Australia GLP-1 buyer's guide · May 2026: Juniper, Pilot, Mosh, LillyDirect, scored honestly

The Australian GLP-1 telehealth market is structurally cleaner than the US equivalent and quietly larger than most international observers realise. Roughly 600,000 Australians filled at least one Ozempic / Mounjaro / Wegovy prescription in 2025 according to PBS data; the total telehealth-mediated cohort runs in the low hundreds of thousands. Three operators dominate the private market · Juniper, Pilot, and Mosh · alongside Eli Lilly's own LillyDirect Australia channel which launched as a direct-prescriber path. There is no Australian compounded-GLP-1 market at the US scale; brand pharmacy supply is the only legitimate route.

This guide is the May 2026 picture. Rubric scores against the same 11-signal methodology we use everywhere, plus what changed for AU readers after the TGA's September 2025 advertising enforcement and the late-2025 class-warning updates.

The regulatory backdrop you need to know

September 2025 · TGA enforcement. The Therapeutic Goods Administration issued infringement notices and removed more than 3,000 online advertisements for weight-loss medicines, citing breaches of advertising rules that prohibit direct-to-consumer promotion of prescription-only medicines. Juniper, Pilot, and similar operators were specifically named in the regulatory commentary. The enforcement targeted advertising language, not supply or operations · the operators continued to ship medication throughout. By November 2025 the TGA published updated advertising guidance, and operators have largely revised their public marketing to comply.

Late 2025 · TGA class warnings. GLP-1 receptor agonist labels now carry warnings on potential suicidal thoughts or behaviours (consistent with the FDA's parallel updates). Tirzepatide additionally carries Australian-specific contraception advice · reduced effectiveness of oral contraception cannot be ruled out around treatment initiation or dose escalation. Patients on combined oral contraceptives are advised to add a barrier method or switch to a non-oral contraceptive method during the first four weeks of treatment and around any dose increase.

LillyDirect Australia · 2025 launch. Eli Lilly opened a direct-prescriber telehealth path for Mounjaro in Australia. Functions as a parallel channel to the multi-brand telehealth operators · simpler if Mounjaro is your specific target, less flexible if you want a multi-medication formulary or coaching wrap.

Compounded GLP-1 · effectively absent. Australia does not have the US-style compounded GLP-1 market. TGA enforcement on unapproved supply has been firm, brand pharmacy distribution is reliable, and the operator economics don't favour compounded routes. This means AU readers face less of the regulatory churn US readers are working through; brand pharmacy is the routable answer.

The three operators · scored

Juniper Australia (scorecard · 65 · routable)

Eucalyptus brand, women's-health framing. Bundles GLP-1 prescription with a structured health-coaching programme · monthly pricing in the $300-500 range covering both consultation + medication + coaching. Largest by reach in the AU GLP-1 telehealth cohort; Eucalyptus group reported approximately A$120.9M revenue across its weight-loss brands in FY2024-25, growing 55% year on year.

Strengths: brand-only formulary (no compounded exposure), AHPRA-registered prescribers, behavioural-program scaffolding produces stickier adherence than pure-Rx telehealth. Mounjaro and Ozempic both stocked.

Watch-points: bundled pricing structure means medication cost is not always cleanly separated from program cost in published rate cards. Pre-November 2025 advertising drew specific TGA scrutiny; current marketing has been revised.

Routing fit: women-identified Australian readers wanting structured behavioural support alongside the prescription. The programme + Rx wrap is the differentiator.

Pilot Australia (scorecard · 64 · routable)

Eucalyptus brand, men's-health framing. Same parent company as Juniper, comparable operational scale, comparable regulatory footprint. Pairs GLP-1 with related primary-care surfaces (hair loss, ED, mental health) under one subscription.

Strengths: brand-only formulary, AHPRA-registered prescribers, integrated primary-care wrap that fits the men-identified-cohort pattern of bundling weight management with related concerns.

Watch-points: same TGA September 2025 enforcement as Juniper (sister brand). Marketing revised post-November 2025 guidance.

Routing fit: men-identified Australian readers using telehealth for multiple primary-care surfaces. The cross-surface bundle is the differentiator vs single-purpose competitors.

Mosh Australia (scorecard · 60 · routable)

Independent men's-health telehealth · not part of Eucalyptus group. Smaller scale than Juniper / Pilot but operates the same brand-pharmacy model and under the same TGA advertising rules.

Strengths: TGA-licensed, AHPRA-registered prescribers, brand-only supply, sustained operation through the 2024-26 GLP-1 demand wave.

Watch-points: smaller compliance footprint than Eucalyptus brands; less third-party scrutiny means fewer public datapoints on operational discipline. Pricing transparency on the medication-vs-coaching split is similar to Juniper / Pilot.

Routing fit: alternative for men-identified readers who want the men's-health-bundle pattern without going to a Eucalyptus brand. Effectively the independent counterweight.

LillyDirect Australia (not yet a Panya scorecard · direct-prescriber path)

Eli Lilly's direct-prescriber telehealth platform, focused on Mounjaro specifically. Cuts out the multi-brand telehealth layer when Mounjaro is your target. Pricing is set by Lilly directly · cash-pay path complement to insurance / private health fund coverage. Currently outside our 11-signal rubric scoring (different operating model · single-brand, manufacturer-direct), but worth knowing about for readers whose specific answer is Mounjaro.

Routing fit: readers committed to Mounjaro specifically and wanting the simplest direct-prescriber path. No coaching wrap, no multi-brand formulary, just the prescription pathway.

What to do today (May 2026)

Three reader profiles, three answers.

Profile 1 · Want the most-flexible multi-brand option

Juniper Australia (women) or Pilot Australia (men). Brand-only formulary, structured coaching, scale + operational track record. The bundled pricing is the trade-off · expect $300-500/mo all-in including medication.

Profile 2 · Specifically want Mounjaro, want to skip the multi-brand layer

LillyDirect Australia. Direct manufacturer path. Simpler pricing structure, no coaching wrap. Best fit if you have outside support (your GP, an existing dietitian) and want telehealth purely for the Rx + supply.

Profile 3 · Want the men's-health independent alternative

Mosh Australia. Independent of Eucalyptus group. Comparable operational basics (TGA, AHPRA, brand pharmacy) at smaller scale.

What we're watching for the next update

• TGA enforcement evolution: Q1 2026 saw the first full quarter under the November 2025 ad guidance; whether enforcement intensity stays high or normalises matters for operator marketing strategies.
• Foundayo (orforglipron) TGA application: FDA approved April 1, 2026; the TGA pathway typically runs 12-18 months behind FDA for a new molecular entity. Expect TGA decision late 2027 or early 2028.
• Compounded GLP-1 enforcement: any Australian operator claiming "compounded" injectable GLP-1 should be treated as a hard hold pending TGA confirmation; the current legitimate market is brand-only.
• PBS coverage expansion: Ozempic / Mounjaro PBS subsidies remain narrow (type 2 diabetes only); a weight-management indication addition is the next political-economic question.

For the May 2026 cross-region regulatory snapshot: /blog/peptide-pulse-may-2026. For the methodology behind every routing call: /blog/11-signals-vendor-rubric. For the UK equivalent: /blog/uk-glp1-may-2026-nhs-update.